Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase Ia/Ib/IIa Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or an LHRH Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

NCT01823835 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01823835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01823835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase Ia/Ib/IIa Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or an LHRH Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Lead sponsor
Genentech, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
December 29, 2014
Completion date
March 13, 2020
Enrollment
152 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer